


Savolitinib

03/20

ALTERNATE NAMES: Volitinib; AZD 6094; HM 5016504; HMPL 504; 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine; (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine; 4-{1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyrazole

CATALOG #: B3006-1 1 mg
B3006-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₇H₁₅N₉

MOLECULAR WEIGHT: 345.4

CAS NUMBER: 1313725-88-0

APPEARANCE: White to off-white powder

PURITY: >98%

SOLUBILITY: ~16 mg/ml in DMSO

DESCRIPTION: Savolitinib is an inhibitor of cMET tyrosine kinase or hepatocyte growth factor receptor (HGFR). It potently inhibits the tyrosine kinase activity of recombinant cMET *in vitro* with an IC₅₀ value of 4 nM. It inhibits proliferation of cell lines SNU-5, SNU-638, Hs746T, SNU-620, GTL16 and IM95m with 50% effective inhibitory concentrations of 0.6 nM, 0.8 nM, 1.3 nM, 3.5 nM, 5.6 nM and 14.7 nM respectively. It shows dose-responsive anti-tumor efficacy in gastric cancer Hs746t xenograft model treated once-daily (0.3 mg/kg, 1 mg/kg or 2.5 mg/kg) orally, for 16 days.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Gavine, P.R., Ren, Y., Han, L., et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. *Mol Oncol.* 9(1):323-33 (2015).

RELATED PRODUCTS:

Capmatinib (Cat. No. B3005)
 Zanubrutinib (Cat. No. B2512)
 Theliatinib (Cat. No. B3004)
 Avapritinib (Cat. No. B2999)
 Avitinib (Cat. No. B2995)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**